10 research outputs found
Recommended from our members
Neutron energy spectrum from 120 GeV protons on a thick copper target
Neutron energy spectrum from 120 GeV protons on a thick copper target was measured at the Meson Test Beam Facility (MTBF) at Fermi National Accelerator Laboratory. The data allows for evaluation of neutron production process implemented in theoretical simulation codes. It also helps exploring the reasons for some disagreement between calculation results and shielding benchmark data taken at high energy accelerator facilities, since it is evaluated separately from neutron transport. The experiment was carried out using a 120 GeV proton beam of 3E5 protons/spill. Since the spill duration was 4 seconds, protoninduced events were counted pulse by pulse. The intensity was maintained using diffusers and collimators installed in the beam line to MTBF. The protons hit a copper block target the size of which is 5cm x 5cm x 60 cm long. The neutrons produced in the target were measured using NE213 liquid scintillator detectors, placed about 5.5 m away from the target at 30{sup o} and 5 m 90{sup o} with respect to the proton beam axis. The neutron energy was determined by time-of-flight technique using timing difference between the NE213 and a plastic scintillator located just before the target. Neutron detection efficiency of NE213 was determined on basis of experimental data from the high energy neutron beam line at Los Alamos National Laboratory. The neutron spectrum was compared with the results of multiparticle transport codes to validate the implemented theoretical models. The apparatus would be applied to future measurements to obtain a systematic data set for secondary particle production on various target materials
環境汚染に対する未確認発生源の寄与率の推定
要旨あり統計科学とリスク解析研究詳
Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry)
Introduction Given an increasing use of dipeptidyl peptidase-4 (DPP-4) inhibitors to treat patients with type 2 diabetes mellitus in the real-world setting, we conducted a prospective observational study (Japan-based Clinical Research Network for Diabetes Registry: J-BRAND Registry) to elucidate the safety and efficacy profile of long-term usage of alogliptin.Research design and methods We registered 5969 patients from April 2012 through September 2014, who started receiving alogliptin (group A) or other classes of oral hypoglycemic agents (OHAs; group B), and were followed for 3 years at 239 sites nationwide. Safety was the primary outcome. Symptomatic hypoglycemia, pancreatitis, skin disorders of non-extrinsic origin, severe infections, and cancer were collected as major adverse events (AEs). Efficacy assessment was the secondary outcome and included changes in hemoglobin A1c (HbA1c), fasting blood glucose, fasting insulin and urinary albumin.Results Of the registered, 5150 (group A: 3395 and group B: 1755) and 5096 (3358 and 1738) were included for safety and efficacy analysis, respectively. Group A patients mostly (>90%) continued to use alogliptin. In group B, biguanides were the primary agents, while DPP-4 inhibitors were added in up to ~36% of patients. The overall incidence of AEs was similar between the two groups (42.7% vs 42.2%). Kaplan-Meier analysis revealed the incidence of cancer was significantly higher in group A than in group B (7.4% vs 4.8%, p=0.040), while no significant incidence difference was observed in the individual cancer. Multivariate Cox regression analysis revealed that the imbalanced patient distribution (more elderly patients in group A than in group B), but not alogliptin usage per se, contributed to cancer development. The incidence of other major AE categories was with no between-group difference. Between-group difference was not detected, either, in the incidence of microvascular and macrovascular complications. HbA1c and fasting glucose decreased significantly at the 0.5-year visit and nearly plateaued thereafter in both groups.Conclusions Alogliptin as a representative of DPP-4 inhibitors was safe and durably efficacious when used alone or with other OHAs for patients with type 2 diabetes in the real world setting